A Phase 1b, Multicenter, 2-Part, Open-Label Study Of DS-1062a In Combination With Durvalumab In Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Prior Immunotherapy